Clinical trials: Borderline Resectable
Pancreatic Neoplasms, Pancreatic Cancer
Project Survival-Prospective Biomarker Discovery
This sample-collection study is open to participants in several categories: healthy volunteers (with or without a family history of pancreatic cancer) and individuals diagnosed with pancreatitis or any stage of pancreatic cancer.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Pancreatitis, Pancreatic Adenocarcinoma
- Trial name
- NCT02781012
- Where
- 6 sites in United States
- Volunteers
- 436 people, healthy volunteers welcome
- Sponsor
- Pancreatic Cancer Research Team
Pancreatic Cancer
A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
This is a two-arm, open-label, phase II study of in adult patients who have successfully undergone R0/R1 resection of PDAs following neoadjuvant chemotherapy and completion of adjuvant chemotherapy.
- Trial name
- NCT03038477
- Testing
- Durvalumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Pancreatic Cancer
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
In this prospective study, new diagnostic tools will be explored for patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (BR or LAPDA) who undergo neoadjuvant chemotherapy with FOLFIRINOX.
- Trial name
- PeRFormanCe (NCT05298722)
- Testing
- Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.
- Where
- 8 sites in Belgium, Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent